Press releases

Beactica expands into new premises

Beactica, the Swedish fragment-based drug discovery company, today announced its move into new premises at the Uppsala Business Park. "The move to the new premises give us excellent opportunities to expand as the company grows.” said Beactica’s COO, Dr Malin Elinder. "Our international collaboration partners will... [...]

Beactica scientists publish strategies for discovery of allosteric modulators

Beactica, the Swedish fragment-based drug discovery company, today announced the publication of a key paper in Proceedings of the National Academy of Sciences*. The paper describes important work towards the discovery of novel drugs targeting ligand-gated ion channels, a significant family of drug targets involved in... [...]

Beactica awarded funding to develop epigenetic cancer drugs

Beactica, the Swedish fragment-based drug discovery company, today announced that it has been awarded a SEK 3.0 million grant from the Swedish Governmental Agency for Innovation Systems (VINNOVA). The grant will be used to support the development of a new epigenetic drug for treatment of cancer. Specifically, the... [...]

Beactica appoints Magnus Björsne to its Board of Directors

Beactica, the Swedish fragment-based drug discovery company, today announced the appointment of Dr Magnus Björsne to its Board of Directors. Dr Björsne, Executive Director at AstraZeneca BioVentureHub, brings more than 15 years of experience from the pharmaceutical industry to the Company. "We are delighted to welcome... [...]

Beactica receives CIR (French Research Tax Credit) accreditation

Beactica today announced that it has received CIR accreditation from the French Ministry of Higher Education and Research. The French R&D tax credit initiative ('Crédit d'Impôt Recherche', CIR) gives eligible research-based companies, who are subject to corporate tax in France, the ability to claim tax... [...]

Beactica initiates drug discovery collaboration with Medivir

Beactica, the Swedish fragment-based drug discovery company, today announced that it has entered into an agreement with Medivir AB (OMX: MVIR). Under the agreement, Beactica will use its proprietary discovery platform to identify novel hits against a disease-relevant protease of therapeutic interest to Medivir. Financial... [...]

Beactica expands its drug discovery collaboration with Boehringer Ingelheim

Beactica today announced that it has expanded its collaboration with Boehringer Ingelheim. For the additional project, Beactica will use its proprietary fragment-based platform to identify novel and selective hits against oncology-relevant kinases of therapeutic interest to Boehringer Ingelheim. Financial terms of the... [...]

Beactica extends fragment-based discovery research services agreement

Beactica, the leading Swedish fragment-based drug discovery company, today announced that it has added a project under its ongoing research services agreement with Janssen Research & Development, a division of Janssen Pharmaceutica NV. Under the research services agreement, Beactica will use its proprietary drug... [...]

Beactica contributes to detailed understanding of innovative cancer drug

Beactica, the Swedish drug discovery company with world-leading expertise in molecular interactions, today announced its contribution to a key paper in the Journal of Pharmacology and Experimental Therapeutics*. As part of a collaboration with Boehringer Ingelheim, Beactica scientists provided important insights into... [...]